Shukla Aakriti Garg

The Impact of COVID-19 on Individuals Across the Spectrum of Visual Impairment.

The pandemic might have had a disproportionate impact on the visually impaired, and evidence-based assessments of COVID-19 health outcomes in this population are warranted.

What Glaucoma Patients Are Reading on the Internet: A Systematic Analysis of Online Glaucoma Content.

The most readily accessible online information about glaucoma varies in content, quality, accuracy, navigability, and readability. This systematic analysis identifies potential areas of improvement.

Outcomes of Valved and Nonvalved Tube Shunts in Neovascular Glaucoma.

Eyes with AGV and BGI had comparable outcomes in NVG, although fewer medications were required in BGI eyes to control IOP.

Reoperation for complications within 90 days of minimally invasive glaucoma surgery.

The rate of reoperation within the first 90 days after MIGS was low. Elevated IOP and complications associated with gel microstents were the main indications for reoperation.

Early Experience with Netarsudil in Pediatric Patients: A Retrospective Case Series.

Correlation between Central Visual Field Defects and Stereopsis in Patients with Early-to-Moderate Visual Field Loss.

Central visual field defects were associated with increased odds of poor stereoacuity in patients with early-to-moderate glaucomatous VF loss.

Descriptive Analysis of United States Glaucoma Fellowship Program Directors.

Improving Outcomes in Neovascular Glaucoma.

American Glaucoma Society-American Academy of Ophthalmology Position Statement on Nicotinamide Use for Glaucoma Neuroprotection.

Kahook Dual Blade Goniotomy Versus iStent Implantation Combined With Phacoemulsification: A Systematic Review and Meta-Analysis.

KDB goniotomy may offer better surgical success compared with Stent implantation when used in combination with phacoemulsification.

Drug-Induced Liver Injury During a Glaucoma Neuroprotection Clinical Trial.

This report is important to share with the medical community, as other participants in glaucoma nicotinamide trials globally may have similar adverse events and many patients are using nicotinamide as a health supplement without medical supervision.

Glaucoma Screening in the Primary Care Setting: Practical and Innovative Approaches.

Topical 0.1% Nepafenac versus 0.09% Bromfenac Eye Drops for Inflammation after Laser Peripheral Iridotomy: A Randomized Controlled Trial.

Topical 0.09% bromfenac is noninferior to 0.1% nepafenac in controlling inflammation after LPI in eyes with PACS and PAC. Nepafenac may be associated with higher patient-reported comfort.

Transscleral Cyclophotocoagulation for Glaucoma in the Setting of Uveal Melanoma.

Outcomes of Baerveldt glaucoma implant and transscleral cyclophotocoagulation in neovascular glaucoma.

Characterization of Temporal Delay and Modeling of Intraocular Pressure and Visual Field Progression in the African Descent and Glaucoma Evaluation Study (ADAGES).

ROP changes trail IOP changes by 4-7 months, an important consideration when obtaining additional VFs to capture or rule-out progression.

Nicotinamide and Pyruvate in Open-Angle Glaucoma: A Randomized Controlled Trial on Neuroprotection-Design and Methodology.

This novel trial design may deliver valuable data on the neuroprotective potential of nicotinamide and pyruvate supplementation in glaucoma and improve our understanding of optimal study design for longitudinal randomized clinical trials focused on glaucoma neuroprotection.

Early Postoperative Aqueous Suppression Therapy and Surgical Outcomes of Ahmed Tube Shunts in Refractory Glaucoma.

Early use of aqueous suppressants may lower the risk of HP and improve AGV outcomes. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.